Division of Hematology Medical Oncology, Division of Internal Medicine, Mayo Clinic Arizona, Phoenix, AZ; and.
Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Phoenix, AZ.
Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):69-74. doi: 10.1182/asheducation-2018.1.69.
The growing body of genomic information collected and applied to mature aggressive B-cell lymphoma diagnosis and management has exploded over the last few years due to improved technologies with high-throughput capacity, suitable for use on routine formalin-fixed, paraffin-embedded tissue biopsies, and decreasing costs. These techniques have made evaluation of complete DNA sequences, RNA-expression patterns, translocations, copy-number alterations, loss of heterozygosity, and DNA-methylation patterns possible on a genome-wide level. This chapter will present a case of aggressive B-cell lymphoma and discuss the most important genomic abnormalities that characterize this group of entities in the recent update to the fourth edition of the World Health Organization (WHO) lymphoma classification system. Genomic abnormalities discussed will include those necessary for certain diagnoses such as translocations of , , or ; gene-expression-profiling categorization; the newly defined Burkitt-like lymphoma with 11q abnormalities; prognostic and predictive mutations, as well as tumor heterogeneity. Finally, our current practices for clinical triage of specimens with a potential diagnosis of aggressive B-cell lymphomas are also described. Options for treatment at relapse, in light of these genomic features, will be discussed in the third presentation from this session.
近年来,由于高通量技术的改进,适用于常规福尔马林固定、石蜡包埋组织活检,且成本降低,收集并应用于成熟侵袭性 B 细胞淋巴瘤诊断和治疗的基因组信息不断增加。这些技术使得评估完整的 DNA 序列、RNA 表达模式、易位、拷贝数改变、杂合性丢失和 DNA 甲基化模式成为可能,达到全基因组水平。本章将介绍一例侵袭性 B 细胞淋巴瘤,并讨论在世界卫生组织(WHO)淋巴瘤分类系统第四版最近更新中,可用于表征此类实体的最重要的基因组异常。讨论的基因组异常包括某些诊断所必需的异常,如易位、或 ;基因表达谱分类;新定义的伴有 11q 异常的伯基特样淋巴瘤;预后和预测性突变,以及肿瘤异质性。最后,还描述了我们目前对可能诊断为侵袭性 B 细胞淋巴瘤的标本进行临床分类的做法。在本次会议的第三个演讲中,将根据这些基因组特征讨论复发时的治疗选择。